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ABSTRACT
Objective: Type 2 diabetes (T2D) and its
complications form a global healthcare burden but the
exact impact in some geographical regions is still not
well documented. We describe the healthcare resource
usage (HRU) associated with T2D in Africa, the Middle
East, South Asia, Eurasia and Turkey.
Research design and methods: In the fifth wave of
the International Diabetes Management Practices Study
(IDMPS; 2011–2012), we collected self-reported and
physician-reported cross-sectional data from 8156
patients from 18 countries across 5 regions, including
different types of HRU in the previous 3–6 months.
Negative binomial regression was used to identify
parameters associated with HRU, using incidence rate
ratios (IRRs) to express associations.
Results: Patients in Africa (n=2220), the Middle East
(n=2065), Eurasia (n=1843), South Asia (n=1195) and
Turkey (n=842) experienced an annual hospitalization
rate (mean±SD) of 0.6±1.9, 0.3±1.2, 1.7±4.1, 0.4±1.5
and 1.3±2.7, respectively. The annual number of
diabetes-related inpatient days (mean±SD) was 4.7
±22.7, 1.1±6.1, 16.0±30.0, 1.5±6.8 and 10.8±34.3,
respectively. Despite some inter-regional heterogeneity,
macrovascular complications (IRRs varying between
1.4 and 8.9), microvascular complications (IRRs
varying between 3.4 and 4.3) and, to a large extent,
inadequate glycemic control (IRRs varying between
1.89 and 10.1), were independent parameters
associated with hospitalization in these respective
regions.
Conclusions: In non-Western countries,
macrovascular/microvascular complications and
inadequate glycemic control were common and
important parameters associated with increased HRU.
INTRODUCTION
Type 2 diabetes (T2D) and its chronic com-
plications are recognized as a global health-
care burden both from a societal and
personal perspective. Among the estimated
8.3% of people with diabetes, 90% have T2D
and the number of affected people is
expected to increase by 55% in 2035.1 In
recent decades, the largest increase in dia-
betes prevalence has been observed in low-
income and middle-income countries
(LMIC) where 80% of people with T2D aged
40–59 years are living in these countries.2 3
This trend is expected to continue in the
next 20 years due to changes in demograph-
ics, lifestyle and economic development.1
According to the International Diabetes
Federation (IDF) Atlas, 10% of adults from
the Middle East and North Africa (MENA)
and South East Asia are expected to have dia-
betes, however, with substantial between-
country variation within the region.1
Diabetes causes microvascular and macro-
vascular complications, mainly driven by
disease duration3 4 with increased risk of pre-
mature mortality across all ages compared
with the general population.5 Diabetes and
Key messages
▪ Results from the International Diabetes
Management Practice Study (IDMPS) wave 5
show high levels of healthcare resource use
(HRU) associated with the presence of type 2
diabetes mellitus in non-Western countries.
▪ The presence of macrovascular/microvascular
complications and insufficient glycemic control
are the most consistent parameters associated
with increased resource use.
▪ Our study re-emphasizes the importance of early
diagnosis and intervention to reduce complica-
tions and HRU and highlights the need for more
national-based surveys with precise separation of
HRU for prevention and treatment of late compli-
cations in order to inform healthcare providers
and policymakers on the socioeconomic burden
of diabetes and its complications.
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its associated complications worsen health-related quality
of life (HRQoL)6–8 with many patients experiencing pro-
blems with self-care, pain/discomfort and anxiety/
depression.6 Patients with comorbidities, and especially
those with vascular diseases, have shown consistently
lower HRQoL than those without.6 7 9 Furthermore,
prevalence of depression in T2D has been estimated to
be twice higher than without.8 10 11
Growing evidence from LMIC shows the burden of
diabetes care in terms of healthcare resource use
(HRU) and costs.12 At an individual level, this has been
attributed largely to the presence of relatively high
out-of-pocket (OOP) treatment costs.12 Such costs have
the potential for a catastrophic impact on incomes,
pushing families below the poverty line.13 In LMIC,
people with diabetes have spent on average $157 per
year more than those without the disease,14 putting
them at a higher risk of incurring catastrophic medical
spending compared with those without diabetes. It has
been reported that around 17.8% of patients with dia-
betes go below the poverty line due to medical OOP
payments compared with 13.9% of patients without dia-
betes.14 Previous reports from the International Diabetes
Management Practice Study (IDMPS) showed the high
resource consumption among patients with T2D from
Asia, Latin America, the Middle East and Africa,15 where
the presence of microvascular/macrovascular complica-
tions and inadequate diabetes control were strong pre-
dictors for hospitalizations. These data highlighted the
urgent need for health policy steps to address the
increasing magnitude of this ongoing public health
problem. In this cross-sectional analysis, we estimated
levels of HRU and their predictors among patients with
T2D recruited from 18 countries in Africa, the Middle
East, South Asia, Eurasia and Turkey.
RESEARCH DESIGN AND METHODS
The IDMPS is an ongoing international multicenter
observational study conducted annually for the past
10 years. Until now, we have collected six waves of data
from non-Western countries to document the pattern of
care in a real-world setting in order to inform practice
and policy. The primary objective of the study is to assess
the HRU of T2D in current medical practice. The sec-
ondary objective is to evaluate the initiation, character-
istics and management of insulin therapy and to assess
the overall health economic impact of T2D and its com-
plications. Speciﬁc outcomes collected as part of wave 5
of the IDMPS included details of management of care,
education and HRU.
Physicians involved in each wave of the IDMPS were
randomly selected at a country level and requested to
enroll the ﬁrst 10 patients with T2D they had a consult-
ation with over a 2-week period. Eligible physicians had
to have experience with initiation and titration of
insulin. Patients younger than 18 years, patients partici-
pating in a clinical study, or patients receiving temporary
insulin treatment because of conditions such as gesta-
tional diabetes, pancreas cancer or surgery at the time
of enrollment were excluded. Patients were also
excluded if they had already participated in a previous
wave of the IDMPS. The sample size was estimated on a
country by country basis, and was calculated such that
the expected relative precision around the proportion of
patients receiving insulin reached 20%.
Each wave of the IDMPS consisted of a cross-sectional
and a longitudinal part. The cross-sectional part was a
2-week survey during which data were collected by physi-
cians through a standardized case report form. Patients
enrolled in the cross-sectional study who were treated
with insulin were eligible to enter a 9-month longitu-
dinal study. Physician details and characteristics were
also collected at study initiation.
Ethical approvals for the IDMPS study were obtained
from the Ethics Committees in all participating coun-
tries and all patients provided written informed consent
prior to enrollment. Study design and reporting format
are in accordance with the Strengthening the Reporting
of Observational Studies in Epidemiology (STROBE)
guidelines.16
Resource consumption data were collected within the
cross-sectional part of the ﬁfth wave of the IDMPS study
(2011–2012). HRU was assessed based on the
patient-reported frequency of visits to endocrinologists/
diabetologists or other physicians (including general prac-
titioners (GPs)), hospitalizations due to diabetes-related
complications (including hypoglycemia), hospital
inpatient days, and emergency room (ER) visits due to dia-
betes complications and work loss (unemployment, absen-
teeism and sick leave) in the past 3 months. Additionally,
patients were asked to report the frequency of ER visits
due to hypoglycemia in the past 6 months and number of
laboratory tests (glycated hemoglobin, HbA1c), self-
monitoring of blood glucose (SMBG) and screenings for
complications in the past year. Details on antidiabetic treat-
ment (eg, oral antihyperglycemic drugs (OADs) by class
and agent, insulin by class and agent, or other) with the
corresponding doses and frequencies of administration
were recorded. Similar information on use of antihyper-
tensive and lipid-lowering drugs was also recorded.
Presence of complications was recorded by the physician
using deﬁnitions included in the case report form.
Levels of HRU were estimated among the 18 countries
stratiﬁed according to regions including South Asia,
Eurasia, the Middle East and Africa with data for Turkey
presented separately, due to its geographical location
and demography. Reported 3-month and 6-month quan-
tities for HRU items were converted to an annual esti-
mate assuming a constant rate of use. For resources
measured as a binary outcome (yes/no), no further
adjustments were made.
Statistical analysis
Descriptive statistics were generated for population
characteristics and levels of HRU. Data related to the
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number of visits to diabetologists/endocrinologists and
other physicians (including GPs), diabetes-related hospi-
talizations, hospital inpatient days, ER visits and number
of days off work due to diabetes were computed on a
country and regional level and expressed as mean±SD
or median (range), depending on distribution. For each
variable, the analysis was performed only on cases with
complete data, that is, cases with missing or unknown
values were excluded.
A generalized linear model based on a negative bino-
mial distribution was used to determine variables asso-
ciated with hospitalizations, hospital inpatient days, ER
visits and absenteeism. We selected these four key items
of HRU because of their high costs. Regression models
were developed separately for each region of interest
with a separate analysis for Turkey.
The following covariates were included in the models:
age (years); time since diagnosis (years); gender (male
or female); body mass index (BMI) at inclusion (≤25,
25–30, 30–35, >35 kg/m2; ≤18.5 was not included due to
limited number of patients); locality (rural, urban and
suburban); education level (illiterate, primary, secondary
and university higher); health insurance (no, public and
private); microvascular complications (present and
absent); macrovascular complications (present and
absent); blood pressure (systolic blood pressure (SBP)/
diastolic blood pressure (DBP) ≤130/80 mm Hg, SBP/
DBP≥130/80 mm Hg); low-density lipoprotein (LDL)
cholesterol (≤100, ≥100 mg/dL); high-density lipopro-
tein (HDL) cholesterol (≤40, ≥40 mg/dL); glycemic
control (HbA1c≤7%, ≥7%); fasting blood glucose
(FBG≤100, ≥100 mg/dL); type of practice of the phys-
ician (public, private, mostly public and mostly private);
specialty of the physician (diabetologist–endocrinologist
and other, including GPs) and countries within the
regions. Variables which were signiﬁcant at a 20%
threshold were included in the multivariate model.
A backward selection method was then applied, with
the ﬁnal model restricted to variables statistically signiﬁ-
cant at the 5% level as well as the country. Complete
case analysis, which involves the discarding of cases
where the dependent variable or any of the identiﬁed
covariates are missing, was applied as the base-case.
Countries with a sample size lower than 50 were
excluded from the HRU multivariate analysis and this
concerned only one country (Senegal). Incidence rate
ratios (IRRs) and corresponding 95% CIs were gener-
ated from the multivariate analysis for each categorical
covariate included in the model. All statistical analyses
were performed using SAS V.8.02 (SAS Institute, Cary,
North Carolina, USA).
RESULTS
Patients
An initial total of 10 987 patients with T2D were
recruited across Africa, the Middle East, South Asia,
Eurasia and Turkey, among whom 8156 met the
inclusion criteria of the IDMPS wave 5. Demographic,
clinical and socioeconomic characteristics of the
included patients are shown in tables 1–3. Gross domes-
tic product per capita at a country level is also pre-
sented. At a regional level, the sample sizes were 2220
patients in Africa, 2065 in the Middle East, 1834 in
Eurasia, 1195 in South Asia and 842 in Turkey. The age
of the patients ranged from 53.7±10.6 years in South
Asia to 55.8±11.5 years in Eurasia and the duration of
disease ranged from 8.3±7.2 years in the Middle East to
9.0±6.7 years in South Asia. The prevalence of micro-
vascular complications was similar across most regions
(35–42%) except Eurasia (≈87%). Furthermore, the
prevalence of macrovascular complications was similar
across most regions (14–20%) except Eurasia (47%).
The proportion of people employed full time or part
time varied between 28% in Turkey and 47% in the
Middle East, although a substantial proportion of
patients were of working age. Proportions of patients
treated with OADs, antihypertensive and lipid-lowering
drugs were generally high across all regions (table 4).
Annual quantities of HRU
Table 3 summarizes the levels of diabetes-related HRU
reported by category, country and region. The number
of annual GP visits reported across the regions varied
between 2.5±7.0 in South Asia and 6.5±7.6 in Eurasia.
Patients in Turkey reported the lowest annual endocrin-
ologist/diabetologist visits of 2.6±4.2 while in Eurasia it
was 11.8±9.0. The annual number of hospitalizations did
not exceed one except in Eurasia (1.7±4.1) and Turkey
(1.3±2.7). Length of hospital stay in terms of inpatient
days was signiﬁcantly (p<0.05) higher in Eurasia and
Turkey (16.0±29.6 and 10.8±34.3, respectively) than
other regions (4.7±22.7 in Africa, 1.1±6.1 in the Middle
East and 1.5±6.7 in South Asia). The number of
diabetes-related ER visits was relatively low across all the
regions with the lowest ﬁgures reported in the Middle
East, Eurasia and South Asia (0.2±1.4) and the highest
in Turkey (0.9±4.1). The number of days off work due to
diabetes per year was highly variable across the regions
with the lowest value recorded in the Middle East (1.4
±6.8) and the highest in Eurasia (17.5±35.4; table 5).
Parameters associated with resource use
The multivariate analysis identiﬁed a number of para-
meters associated with increased numbers of hospitaliza-
tions, inpatient days, ER visits and absenteeism. Drivers
of healthcare consumption in the four categories in the
analysis included: the type of physician practice (public
vs private), glycemic control (HbA1c≥7% vs ≤7%),
gender (male vs female), HDL cholesterol (HDL≤40 vs
≥40 mg/dL), hypertension (SBP/DBP≤130/80 vs
≥130/80 mm Hg), BMI (≤25 vs (30; 35); (25; 30) vs (30;
35); (30;35) vs >35 kg/m2), time since diagnosis (≤10 vs
≥10 years), locality (suburban vs urban), education level
(university vs secondary), health insurance (yes vs no) as
well as the presence of microvascular and macrovascular
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Table 1 Demographic characteristics of patients with T2DM by country and region
Mean SD,
age years
Females
(%)
Ethnicity
Caucasian
n (%)
South
Asian
(%)
Black
(%)
Oriental,
Arab,
Persian (%)
Japanese
(%)
Other
Asian
(%)
Other
(%)
Eurasia (n=1835) 58.8 (9.6) 60 64 0.4 0.0 0.1 0.1 20.8 14.9
Georgia (n=152) 59.6 (10.1) 47 99 0.0 0.0 0.0 0.0 0.0 0.7
Kazakhstan (n=413) 57.4 (10.4) 60 33 0.0 0.0 0.0 0.2 9.2 57.9
Russia (n=540) 61.7 (9.3) 71 98 0.0 0.0 0.0 0.0 1.7 0.2
Ukraine (n=354) 57.5 (9.1) 57 91 0.3 0.0 0.0 0.0 0.0 8.5
Uzbekistan (n=376) 57.2 (8.3) 52 8 1.9 0.0 0.5 0.0 88.8 0.8
Africa (n=2269) 57.4 (10.8) 57 46 0.0 25.2 28.9 0.0 0.0 0.0
Algeria (n=515) 59.4 (10.7) 59 96 0.0 0.2 3.7 0.0 0.0 0.0
Cameroon (n=525) 57.4 (11.0) 61 0 0.0 100.0 0.0 0.0 0.0 0.0
Egypt (n=371) 53.9 (10.6) 52 0 0.0 0.0 100.0 0.0 0.0 0.0
Morocco (n=499) 58.0 (10.5) 62 99 0.0 0.0 0.6 0.0 0.0 0.0
Senegal (n=46) 58.4 (8.5) 65 0 0.0 100.0 0.0 0.0 0.0 0.0
Tunisia (n=313) 57.5 (10.1) 42 16 0.0 0.0 84.0 0.0 0.0 0.0
Middle East (n=2067) 55.8 (11.5) 48 2 4.3 0.6 91.6 0.0 1.4 0.3
Jordan (n=296) 54.8 (10.7) 46 0 0.3 0.3 99.0 0.0 0.0 0.0
KSA (n=199) 52.4 (10.4) 40 10 8.0 1.0 79.9 0.0 1.5 0.0
Lebanon (n=1061) 58.2 (11.1) 49 0 0.0 0.0 99.6 0.0 0.0 0.1
UAE (n=511) 52.7 (11.9) 49 3 14.1 2.0 75.3 0.0 5.1 1.0
South Asia (n=1196) 53.7 (10.6) 44 0 94.8 0.0 0.1 0.0 4.3 0.8
India (n=994) 53.8 (10.6) 44 0 93.9 0.0 0.0 0.0 5.1 1.0
Pakistan (n=202) 53.3 (11.0) 44 0 99.5 0.0 0.5 0.0 0.0 0.0
Turkey (n=842) 56.9 (11.4) 55 98 0.1 0.0 0.4 0.0 0.0 1.4
KSA, Kingdom of Saudi Arabia; T2DM, type 2 diabetes mellitus; UAE,United Arab Emirates.
Table 2 Socioeconomic characteristics of patients with T2DM by country and region
GDP/
capita
(US$)*
Location Education Employed
(full time
or part
time) (%)
Urban
area
(%)
Rural
area
(%)
Suburban
area (%)
Illiterate
(%)
Primary
(%)
Secondary
(%)
Higher
(%)
Eurasia (n=1835) – 82.5 15.1 2.4 0.1 1.9 49.2 48.8 38.0
Georgia (n=152) 3520 77.2 19.5 3.4 0.0 0.0 38.3 61.7 36.0
Kazakhstan (n=413) 11 983 85.0 14.5 0.5 0.0 0.7 53.4 45.9 41.0
Russia (n=540) 14 302 96.9 1.7 1.5 0.0 2.6 53.8 43.6 38.0
Ukraine (n=354) 3877 75.6 20.1 4.3 0.3 3.0 49.0 47.8 43.0
Uzbekistan (n=376) 1736 67.5 28.8 3.7 0.3 2.0 42.1 55.7 33.0
Africa (n=2269) – 84.5 10.1 5.4 21.4 28.9 31.7 18.1 35.0
Algeria (n=515) 5583 87.2 7.8 5.1 26.4 36.5 30.4 6.7 24.0
Cameroon (n=525) 1181 78.7 12.3 9.0 10.2 31.8 39.7 18.3 35.0
Egypt (n=371) 3112 83.3 14.0 2.7 12.4 20.5 24.8 42.3 48.0
Morocco (n=499) 2956 88.2 8.4 3.4 36.8 28.7 25.1 9.5 32.0
Senegal (n=46) 1074 65.2 13.0 21.7 50.0 13.6 22.7 13.6 32.0
Tunisia (n=313) 4213 87.8 8.0 4.2 13.3 24.2 40.8 21.8 43.0
Middle East (n=2067) – 76.5 15.7 7.8 10.3 29.9 34.0 25.9 47.0
Jordan (n=296) 4879 89.9 6.1 4.1 1.7 15.7 37.9 44.7 45.0
KSA (n=199) 24 524 92.5 5.0 2.5 15.2 25.8 23.7 35.4 52.0
Lebanon (n=1061) 10 311 59.2 27.5 13.3 6.0 40.8 34.7 18.5 48.0
UAE (n=511) 43 774 98.4 1.0 0.6 22.2 17.1 34.3 26.5 45.0
South Asia (n=1196) – 73.5 15.9 10.7 8.1 17.8 30.7 43.4 45.0
India (n=994) 1501 73.9 13.9 12.2 4.8 15.5 32.4 47.3 46.0
Pakistan (n=202) 1261 71.1 25.9 3.0 24.5 29.2 22.4 24.0 40.0
Turkey (n=842) 10 527 80.6 14.5 4.9 15.4 46.3 26.7 11.7 28.0
*IMF estimates for 2012.
GDP, gross domestic product; IMF, International Monetary Fund; KSA, Kingdom of Saudi Arabia; T2DM, type 2 diabetes mellitus; UAE,United
Arab Emirates.
4 BMJ Open Diabetes Research and Care 2017;5:e000297. doi:10.1136/bmjdrc-2016-000297
Epidemiology/health services research
copyright.
 on N
ovem
ber 11, 2019 by guest. Protected by
http://drc.bm
j.com
/
BM
J O
pen D
iab R
es C
are: first published as 10.1136/bm
jdrc-2016-000297 on 17 January 2017. D
ow
nloaded from
 
complications. The signiﬁcance of each parameter
varied between the different healthcare consumption
items and also between the different regions. Glycemic
control and presence of complications were the most
consistent parameters associated with high HRU across
the different regions. The effects of the most common
drivers are presented in ﬁgure 1A–C.
The presence of diabetes-related complications
(macrovascular and microvascular) was the most
common driver of resource use with the largest effect
size. Patients with macrovascular complications had
increased annual rates of hospitalizations across all
regions with IRRs (CI 95%) between 1.4 (1.1 to 1.8;
Eurasia) and 8.6 (4.6 to 15.7; the Middle East) com-
pared with patients with no complications. Similar
results were observed with regard to rates of inpatient
days and ER visits with IRR (CI 95%) ranges of 1.58 (1.2
to 2.1; Eurasia) and 13.4 (4.9 to 36.9; the Middle East)
as well as 2.9 (2.2 to 3.9; Eurasia) and 7.7 (1.8 to 33.8;
South Asia), respectively. The effect of macrovascular
complications was signiﬁcant on rates of absenteeism for
Africa, Eurasia and the Middle East with IRRs (CI 95%)
of 5.2 (1.5 to 18.3), 2.3 (1.5 to 3.6) and 8.3 (2.3 to 29.0).
Similarly, microvascular complications were associated
with increased risk of hospitalizations in all regions with
IRRs (CI 95%) of between 3.5 (2.0 to 6.2; Eurasia) and
4.3 (2.6 to 7.2; Africa). Furthermore, such complications
were also associated with a higher rate of inpatient days
with IRRs (CI 95%) of between 2.3 (1.2 to 4.4; Turkey)
and 7.1 (4.1 to 12.1; Africa). Microvascular complica-
tions were associated with an increased rate of ER visits
in the Middle East, South Asia and Turkey with IRRs (CI
95%) of 2.4 (1.7 to 3.4), 6.2 (2.4 to 15.8) and 6.1 (3.1 to
12.2), respectively. Absenteeism was also higher in
patients with microvascular complications in Africa,
Eurasia and South Asia with IRRs (CI 95%) of 5.9 (2.7
to 12.6), 4.0 (2.3 to 7.2) and 6.5 (2.7 to 15.8),
respectively.
DISCUSSION
Despite the wealth of information on the economic
impact of T2D and its complications in Western coun-
tries, the magnitude of this burden in non-Western
countries is relatively unknown. In this ﬁrst-ever multi-
national report on healthcare resource consumption
including 18 countries across Africa, the Middle East,
South Asia, Eurasia and Turkey and comprising 8156
patients with T2D, we have identiﬁed large inter-regional
variations in the different HRU items. Despite this het-
erogeneity which may be attributed to differences in the
healthcare system as well as clinical practices, the pres-
ence of macrovascular/microvascular complications and
poor glycemic control were the most signiﬁcant and
Table 3 Clinical characteristics of patients with type 2 diabetes analyzed in the IDMPS wave 5 by region and country
Country/region
Current
smoker
(%)
Mean
(SD)
diabetes
duration
(years)
Screened for
diabetes-related
complications
(%)*
With
microvascular
complications
(%)*
With
macrovascular
complications
(%)*
With
HbA1c<7%
(%)
Familial
history
of T2DM
(%)
Eurasia (n=1834) 9.8 8.7 (7.1) 99 87 47 21 37.9
Georgia (n=152) 13.2 10.7 (8.6) 99 91 74 4 42.8
Kazakhstan (n=413) 11.1 8.1 (7.3) 100 89 40 21 27.4
Russia (n=540) 9.3 9.5 (7.4) 99 81 42 29 40.9
Ukraine (n=353) 8.5 9.2 (6.3) 97 89 53 15 41.8
Uzbekistan (n=376) 8.8 6.8 (5.7) 100 89 47 23 39.6
Africa (n=2220)† 8.1 8.6 (7.2) 93 41 14 31 52.3
Algeria (n=514) 4.5 8.8 (7.1) 97 41 15 44 51.3
Cameroon (n=524) 2.7 6.6 (6.9) 90 48 6 28 44.5
Egypt (n=371) 17.8 9.4 (7.7) 93 47 20 22 58.2
Morocco (n=498) 5.0 9.0 (7.0) 91 30 15 27 53.7
Tunisia (n=313) 16.9 10.0 (6.7) 98 39 15 23 58.5
Middle East (n=2065) 22.9 8.3 (7.2) 96 35 15 37 59.5
Jordan (n=296) 28.7 6.6 (5.9) 93 30 15 34 55.4
KSA (n=199) 18.6 10.2 (8.2) 94 48 19 31 63.3
Lebanon (n=1059) 28.0 8.1 (7.2) 95 35 17 36 60.4
UAE (n=511) 10.6 9.1 (7.0) 99 30 10 42 58.3
South Asia (n=1195) 8.8 9.0 (6.7) 91 41 14 25 43.2
India (n=994) 7.7 9.1 (6.5) 91 37 11 26 43.0
Pakistan (n=201) 14.4 8.2 (7.2) 92 62 27 22 44.6
Turkey (n=842) 14.5 8.7 (6.8) 94 42 20 28 55.5
*Missing data are considered for percentage calculations.
†Owing to the small sample size (N=50), Senegal was not included in Africa results in this table.
HbA1c, glycated hemoglobin; KSA, Kingdom of Saudi Arabia; T2DM, type 2 diabetes mellitus; UAE,United Arab Emirates.
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consistent drivers for HRU. In this light, disease dur-
ation is the most important driver for complications
which is particularly relevant to patients with young
onset of disease. Of note, the majority of patients were
in the working age with a mean age of 50 years and
disease duration of over 5 years. In Asia, 20% of adult
patients have young onset T2D, that is, diagnosed before
the age of 40. Compared with their peers with late onset
disease, these patients have worse control of risk factors
and are at 1.5 times higher risk for developing cardiovas-
cular–renal events and related death at any age.17 18
These ﬁndings highlighted the burden of late complica-
tions calling for timely management of diabetes to
reduce complications and HRU.15
Several systematic literature reviews have highlighted
the economic burden of diabetes in Asia, notably India
where the presence of complications increased the cost
by three times compared with those without complica-
tions.19–21 A large proportion of this cost is related to
hospitalization rates, which if reduced can sharply
reduce the personal and socioeconomic burden due to
diabetes.22 Similarly, in Turkey, management of diabetes-
related complications accounted for more than half of
the total cost associated with T2D.23 In this multi-
national survey, patients from Eurasia had a much
higher prevalence of macrovascular and microvascular
complications than other regions (47% and 87%,
respectively). However, among different countries in this
region (Georgia, Russia, Kazakhstan, Ukraine and
Uzbekistan), the data were relatively consistent. Similarly,
a high prevalence of macrovascular and microvascular
comorbidities has also been reported in Russia com-
pared with China, Asia, MENA and Latin American
regions.24 These high prevalence rates, which may be
due to a number of population-speciﬁc and system-
speciﬁc factors including low levels of awareness, over-
diagnosis, late presentation and/or suboptimal care,
need further investigation to inform practice and policy
within these countries. The organization of healthcare
delivery in the Eurasian region can also be taken into
account when trying to explain some of the HRU vari-
ability observed in the IDMPS wave 5. The free nature of
the system at the point of delivery as well as prescribing
practices could explain higher levels of hospitalizations
as well as outpatient visits seen in the study compared
with other geographies.25
In the MENA region, the IDF estimates that ∼US$13.6
billion have been spent on treatment of diabetes in
20131 with large regional variations ranging from US
$1605 per person in the United Arab Emirates to US
$175 in Sudan. Despite these differences, spending and
resource usage have been consistently shown to be
tightly associated with the presence of diabetes-related
comorbidities.26 27 Despite the large body of evidence
Table 4 Medical treatment received by recruited patients with type 2 diabetes by region/country
Country/region
On OAD
treatment
(%)
On insulin
treatment
(%)
With
hypertension
(%)
On
antihypertensive
treatment (%)*
With
dyslipidemia
(%)
On
lipid-lowering
treatment (%)†
Eurasia (n=1834) 76 50 84 98 75 83
Georgia (n=152) 41 100 80 100 73 99
Kazakhstan (n=413) 84 40 83 98 71 89
Russia (n=540) 76 53 88 99 69 78
Ukraine (n=353) 83 42 81 98 77 72
Uzbekistan (n=376) 76 47 82 98 84 86
Africa (n=2220)‡ 83 38 57 98 47 84
Algeria (n=514) 92 42 69 99 56 92
Cameroon (n=524) 71 35 53 96 36 60
Egypt (n=371) 83 37 55 100 44 95
Morocco (n=498) 84 36 53 97 46 87
Senegal (n=50) 82 20 52 92 46 46
Tunisia (n=313) 85 43 56 99 53 90
Middle East (n=2065) 94 23 62 99 74 95
Jordan (n=296) 96 19 65 99 71 93
KSA (n=199) 93 32 54 100 68 99
Lebanon (n=1059) 93 23 61 98 72 94
UAE (n=511) 95 23 64 100 83 98
South Asia (n=1195) 93 33 61 98 54 94
India (n=994) 94 33 60 98 56 95
Pakistan (n=201) 89 31 61 98 45 89
Turkey (n=842) 81 46 63 98 56 86
*Among patients with hypertension.
†Among patients with dyslipidemia.
‡Owing to the small sample size (N=50), Senegal was not be included in Africa results in this table.
KSA, Kingdom of Saudi Arabia; OAD, oral antihyperglycemic drug; UAE,United Arab Emirates.
6 BMJ Open Diabetes Research and Care 2017;5:e000297. doi:10.1136/bmjdrc-2016-000297
Epidemiology/health services research
copyright.
 on N
ovem
ber 11, 2019 by guest. Protected by
http://drc.bm
j.com
/
BM
J O
pen D
iab R
es C
are: first published as 10.1136/bm
jdrc-2016-000297 on 17 January 2017. D
ow
nloaded from
 
conﬁrming the preventable nature of these complica-
tions through optimal control of cardiometabolic risk
factors using various strategies including diabetes educa-
tion, self-care, team-based management and use of med-
icines,28 29 globally, most of the diabetes-related
expenditures were on expensive interventions and tech-
nologies rather than on building capacity, developing
infrastructures and implementing community-based pre-
vention programs. In the MENA region, up to 70% of
the healthcare budget is allocated to secondary care
with considerably less being spent on health promotion
and primary care services.30–33
In addition to HRU, we have also reported the impact
of diabetes on absenteeism in regions outside Europe
and North America where data are scarce. In 2013, a sys-
tematic review reported the burden of diabetes on the
ability to work but did not identify any high-quality
studies from countries and regions covered by the
current IDMPS.34 These absenteeism data have major
implications on the person, family and society due to
loss of productivity, especially in those still in employ-
ment.35 In the wave 2 of IDMPS including 24 countries
in Asia, Latin America, the Middle East and Africa, we
also found associations between chronic complications
and absenteeism (14). In the current analysis, there
were relatively high rates of unemployment with marked
inter-regional and intercountry variations in the report-
ing of absenteeism, which could explain the negative
association. In Eurasia, the high absenteeism rate was
driven by data from Kazakhstan, Ukraine and
Uzbekistan while the reporting rates from Russia and
Georgia were more in line with the other regions.
Although our study focuses on non-Western countries,
conclusions from the analysis support ﬁndings from
studies conducted in other parts of the world.
Associations between glycemic control and presence of
complications and increased HRU have been reported in
the USA as well as countries from Western Europe.36–40
An analysis of nearly 10 000 patients treated in a
managed care organization revealed that those with
uncontrolled glycemia (HbA1c≥10%) were more than
twice as likely to be hospitalized due to diabetes than
those with normal HbA1c (<7%).36 Additionally, the cost
of management of patients with microvascular and
macrovascular complications has been estimated to be up
to three times higher than that of complication-free
patients owing to the higher HRU among them.38 40
Despite the increased HRU and costs associated with
diabetes, certain care items are considered beneﬁcial.
For example, increases in screening for complications,
HbA1c testing, SMBG, diabetes education and medica-
tion use are linked to positive long-term health beneﬁts
Table 5 Annual quantities of diabetes-related resource use for patients with type 2 diabetes by region/country
Country/region
Number
of other
physician
visits
including
GP visits
Number of
endocrinologist/
diabetologist
visits
Number of
hospitalizations
due to diabetes
Number
of days of
inpatient
care
Number of
emergency
room visits
Number (%)
unemployed
because of
diabetes*
Number
of sick
leave
days
Eurasia (n=1834) 6.5 (7.6) 11.8 (9.0) 1.7 (4.1) 16.0 (29.6) 0.2 (0.9) 184 (10.0) 17.5 (35.4)
Georgia (n=152) 1.8 (3.7) 11.8 (5.6) 0.4 (1.4) 1.8 (7.6) 0.0 (0.3) 11 (7.2) 5.0 (20.5)
Kazakhstan (n=413) 7.0 (6.1) 11.3 (6.9) 1.9 (2.9) 19.4 (30.1) 0.3 (1.1) 34 (8.2) 23.6 (40.6)
Russia (n=540) 7.0 (9.0) 9.6 (7.6) 0.7 (1.6) 9.5 (26.9) 0.2 (0.9) 47 (8.7) 8.2 (21.8)
Ukraine (n=353) 5.4 (6.4) 11.7 (9.3) 2.9 (7.6) 20.3 (34.3) 0.3 (1.2) 38 (10.8) 23.4 (42.3)
Uzbekistan (n=376) 7.9 (7.8) 15.4 (12.1) 2.3 (3.2) 23.6 (29.9) 0.1 (0.6) 54 (14.4) 22.9 (37.5)
Africa (n=2220)† 3.8 (5.8) 4.3 (5.2) 0.6 (1.9) 4.7 (22.7) 0.4 (1.7) 47 (2.1) 11.6 (44.4)
Algeria (n=514) 3.7 (4.4) 2.3 (3.9) 0.24 (1.0) 2.9 (18.3) 0.2 (0.8) 7 (1.4) 4.1 (25.3)
Cameroon (n=524) 6.9 (8.2) 5.7 (6.2) 0.9 (2.2) 9.9 (36.0) 0.6 (1.7) 23 (4.4) 29.5 (75.1)
Egypt (n=371) 3.2 (6.1) 7.4 (7.2) 0.7 (2.7) 3.8 (20.7) 0.4 (1.5) 6 (1.6) 10.3 (35.7)
Morocco (n=498) 2.0 (3.9) 3.6 (3.2) 0.6 (1.8) 3.3 (12.2) 0.6 (2.5) 7 (1.4) 4.3 (14.4)
Tunisia (n=313) 2.7 (3.7) 3.9 (3.6) 0.4 (1.4) 2.1 (9.3) 0.3 (1.5) 4 (1.3) 4.5 (23.1)
Middle East (n=2065) 4.4 (6.7) 3.8 (4.7) 0.3 (1.2) 1.1 (6.1) 0.2 (1.0) 19 (0.9) 1.4 (6.8)
Jordan (n=296) 5.2 (4.9) 2.3 (3.6) 0.3 (1.4) 1.4 (7.7) 0.2 (0.9) 4 (1.4) 3.4 (12.0)
KSA (n=199) 6.1 (8.4) 4.6 (5.8) 0.4 (1.4) 2.0 (8.3) 0.4 (1.5) 3 (1.5) 2.1 (6.7)
Lebanon (n=1059) 2.0 (3.8) 4.4 (4.1) 0.3 (1.2) 1.1 (5.3) 0.1 (0.8) 8 (0.8) 0.7 (4.1)
UAE (n=511) 8.1 (9.0) 3.2 (5.6) 0.2 (1.0) 0.6 (5.3) 0.2 (1.2) 4 (0.8) 1.6 (7.6)
South Asia (n=1195) 2.5 (7.0) 8.8 (7.6) 0.4 (1.5) 1.5 (6.7) 0.2 (1.4) 26 (2.2) 4.6 (19.7)
India (n=994) 1.0 (3.3) 9.5 (7.6) 0.3 (1.2) 1.2 (5.8) 0.1 (0.9) 20 (2.0) 3.9 (18.9)
Pakistan (n=201) 11.6 (13.7) 4.2 (6.5) 0.8 (2.6) 3.0 (10.4) 0.8 (2.8) 6 (3.0) 8.8 (23.4)
Turkey (n=842) 5.3 (6.0) 2.6 (4.2) 1.3 (2.7) 10.8 (34.3) 0.9 (4.1) 43 (5.1) 8.0 (34.4)
*The whole population is considered for percentage calculations.
†Owingto the small sample size (N=50), data from Senegal were not included in this table.
GP, general practitioner; KSA, Kingdom of Saudi Arabia; UAE, United Arab Emirates.
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and can lead to cost savings.41 42 In a recent analysis of a
large clinical laboratory database, patients who had
three-monthly measurements of HbA1c were found to
have the best glycemic control.42 In a 7-year prospective
survey of Chinese patients with T2D, lack of monitoring
of HbA1c and/or lipids was associated with a 15-fold
increased risk of death compared with those who had at
least one measurement.43 In wave 1 of the IDMPS, a
high level of general education was associated with
increased likelihood of attaining the HbA1c goal
(<7%).44 In wave 2, better educated patients consumed
more healthcare resources in terms of specialist visits,
insulin use and SMBG, with the latter being independ-
ently associated with improved glycemic control.45 In the
current analysis, patients receiving public care were
more likely to be hospitalized than those receiving
private care, although the signiﬁcance requires further
exploration.
Our study has several limitations. Despite the relatively
large number of patients recruited from 18 countries
with fairly consistent results across countries, extrapola-
tion of these multinational data on HRU might not be
applicable to individual countries due to potential selec-
tion bias. Further, physicians participating in the IDMPS
had to have experience in insulin initiation which might
not be representative of the majority of care providers for
people with diabetes. Since these patients were managed
by experienced physicians, they might also be referral
biases since patients with poor risk factor control or com-
plications were more likely to receive specialist care. The
latter was further inﬂuenced by availability of medical
cover or insurance. While these factors might increase
the HRU rate, owing to the volunteer nature of the
survey, the representation of the countries does not fully
reﬂect its demographic weight in the region with only
India and Pakistan representing South Asia.
CONCLUSION
In the IDMPS wave 5, T2D was associated with high
levels of HRU among patients in Africa, the Middle East,
South Asia and Eurasia. Macrovascular/microvascular
complications and insufﬁcient glycemic control were the
most consistent parameters associated with such HRU.
These ﬁndings are consistent with previously reported
IDMPS data collected between 2006 and 2007 indicating
a persistent need for change on a healthcare system
level. While these data re-emphasize the importance of
early diagnosis and intervention to reduce complications
and HRU, more national-based surveys with precise sep-
aration of HRU for prevention and treatment of late
complications will be needed to inform healthcare provi-
ders and policymakers regarding the socioeconomic
burden of diabetes and its complications.
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